Le Lézard
Classified in: Health
Subject: FDA

Breckenridge Announces Final Approval of its ANDA for Imatinib Mesylate Tablets (RLD: Gleevec®)

BOCA RATON, Fla., March 4, 2019 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Imatinib Mesylate Tablets, generic for Gleevec® Tablets by Novartis.  Breckenridge's Imatinib Mesylate Tablets product was developed in collaboration with Stason Pharmaceuticals Inc. and will be commercially manufactured by Stason in 100mg and 400mg product strengths. Breckenridge plans to launch the product in the near future.

The product generated annual sales of approximately $654.8 million over the year ending December 31, 2018, according to industry sales data.

About Breckenridge:
Breckenridge Pharmaceutical, Inc. is a privately held own-label distributor that performs pharmaceutical marketing, research and development, as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms, including: tablets, capsules, liquids, suspensions, ophthalmics, nasal sprays, powders and injectable products.

About Stason:
With strong business ties to pharmaceutical interests in China, Japan, and Taiwan, Stason Pharmaceuticals, Inc., established in 1994 and based in Irvine, CA, is a privately held pharmaceutical company involved in drug development, manufacturing, importation and exportation, licensing and acquisition of both generic and branded products. The company's primary area of development is in the area of oncology, and supportive products for the treatment of side effects related to cancer therapy. Additional therapeutic areas include cardiovascular, central nervous system, autoimmune and endocrine disorders.

Gleevec® is a registered trademark of Novartis.

SOURCE Breckenridge Pharmaceutical, Inc.

These press releases may also interest you

at 04:05
ProteinQure, a leader in computational protein drug discovery, announces a collaboration with the global biopharmaceutical company AstraZeneca to apply structure-based design to the creation of therapeutic libraries with the aim of accelerating the...

at 04:00
Materia ("Materia" or the "Company"), a medical cannabis and CBD wellness company focused on the European market, today announced an agreement with Pure Ratios Holdings Inc. ("Pure Ratios"), an award-winning CBD topical manufacturer and subsidiary of...

at 03:33
IRLAB announced today that a scientific paper reporting the distinctive pharmacological profile of IRL752, in development for the treatment of impaired balance and falls in Parkinson's disease, is accepted and published online in the Journal of...

at 03:05
Forbion, a leading European life sciences venture capital firm, today announces the first close at EUR 185 million (USD 208 million) of its new Forbion Growth Opportunities Fund ("Forbion Growth"), focused on investing in late-stage European life...

at 03:05
transcosmos inc. hereby announces that the company has signed a partnership agreement with dbE., Inc. (Headquarters: Osaka, Japan). With this new partnership, transcosmos will begin offering "rodanius for Pharma," their innovative solution designed...

at 03:05
PathSensors Inc., a Baltimore biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has expanded the company's exclusive license to include clinical applications for CANARYtm technology. This broader license allows...

News published on 4 march 2019 at 13:30 and distributed by: